Lexaria Bioscience Corp.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a LEXX research report →
Range $1.5 – $1.5
Price Chart
About the company
Lexaria Bioscience Corp. is a biotechnology company focused on advanced drug delivery. Its proprietary and patented DehydraTECH technology is designed to significantly improve the oral delivery of active pharmaceutical ingredients, enhancing their absorption into the bloodstream.
- CEO
- Richard C. Christopher
- IPO
- 2021
- Employees
- 7
- HQ
- Kelowna, BC, CA
Get TickerSpark's AI analysis on LEXX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $6.66M
- P/E
- -0.84
- Fwd P/E
- 0.20
- PEG
- -0.01
- P/S
- 38.25
- P/B
- 1.57
- EV/EBITDA
- -0.53
- Div Yield
- 0.00%
- Gross Margin
- 100.00%
- Op Margin
- -3973.16%
- Net Margin
- -3985.58%
- ROE
- -160.72%
- ROIC
- -173.96%
Latest fiscal year · YoY change
- Revenue
- $705.92K+52.0%
- Gross Profit
- $703.20K+53.1%
- Op Income
- $-11,880,737
- Net Income
- $-11,901,841-105.4%
- EPS
- $-9.90-40.4%
- OCF Growth
- -110.7%
- FCF Growth
- -109.4%
- 52W High
- $21.60
- 52W Low
- $2.43
- 50D MA
- $3.48
- 200D MA
- $8.44
- Beta
- 0.34
- RSI (14)
- 49
- Avg Volume
- 70.14K
No earnings-call transcripts are available for LEXX yet.
- Free Float
- 97.0%
- Shares Outstanding
- 1.65M
- Float Shares
- 1.60M
of shares held by institutions
28 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 258.82K | 0 |
| Citadel Advisors LLC | 156.94K | ▲ 143.43K |
Held by 7 ETFs
Biggest fund positions in LEXX by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 17, 26 | BUNKA CHRISTOPHER | other | 100,000 |
| Jul 30, 25 | BUNKA CHRISTOPHER | buy | 11,900 |
| Jul 29, 25 | BUNKA CHRISTOPHER | buy | 15,600 |
| Jul 29, 25 | McKechnie William Edward | buy | 5,000 |
| Jul 29, 25 | DOCHERTY JOHN MARTIN | buy | 5,376 |
| Jul 29, 25 | Carle Vanessa | buy | 750 |
| Jul 29, 25 | CHRISTOPHER RICHARD | buy | 15,000 |
| May 15, 25 | CHRISTOPHER RICHARD | other | 150,000 |
| May 15, 25 | BUNKA CHRISTOPHER | other | 11,000 |
| May 15, 25 | Carle Vanessa | other | 15,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our LEXX coverage
Recent articles, reports, and earnings notes.
No research on LEXX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate LEXX report →Lexaria's Human Study GLP-1-H26-7 Completes Dosing as Scheduled
thenewswire.com · Nov 19
Lexaria Enters a New Pharmaceutical Agreement for DehydraTECH
thenewswire.com · Nov 4
Lexaria Celebrates its 70th Patent Award
thenewswire.com · Oct 28
Lexaria's Human Study GLP-1-H26-7 Reaches Full Enrollment and Continues Dosing on Schedule
thenewswire.com · Oct 21
Lexaria's Human Study GLP-1-H26-7 Reaches Full Enrollment and Continues Dosing on Schedule
accessnewswire.com · Oct 21
Lexaria Announces Results from Animal Study GLP-1-A26-1
accessnewswire.com · Oct 15
Lexaria Announces Results From Animal Study GLP-1-A26-1
thenewswire.com · Oct 15
GLP-1 Weight-Loss/Diabetes Industries Continue Transition to Oral Medications
thenewswire.com · Oct 6
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.